NasdaqGM:RLAYBiotechs
Relay Therapeutics (RLAY) Stock Valuation After Analyst Upgrades On Early Zovegalisib Data
Recent analyst upgrades for Relay Therapeutics (RLAY) focus on early clinical data for its drug candidate zovegalisib. Initial results in PIK3CA-driven vascular anomalies, particularly in heavily treated patients, have drawn increased attention to the stock.
See our latest analysis for Relay Therapeutics.
The recent enthusiasm around zovegalisib comes on top of strong price momentum, with a 1-month share price return of 21.39%, a 3-month share price return of 46.20% and a year-to-date share...